Daniel Estandian

CR Certification Corp. provides online portals for archiving, beready training, and cardioready training. The private company is based in Malvern, PA. The company also offers assistance in selecting automated external defibrillators (AEDs) through their ultimate buyer's guide and resource center pages.

HealthTell, Inc. develops healthcare diagnosing tools for individuals to monitor their health status. It offers OneTest, a new technology for the early detection and monitoring of progressive diseases and the test is simple and inexpensive, and can be performed with only a single drop of blood. The company was founded in 2010 by Stephen Albert Johnston and Neal Woodbury and is headquartered in Chandler, AZ.

Circadence Corp. provides WAN and network optimization solutions for commercial, healthcare and government customers. Its WAN optimization portfolio includes patented Transport Morphing Protocol (TMP), which is built into the Circadence MVO solution. The company was founded by Christopher T. Blisard, Tony Harman and Michael J. Moniz in 1993 and is headquartered in Boulder, CO.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses

Clinverse, Inc. provides automated financial management technology solutions for clinical trials. The firm’s products include ClinPay, ClinDebit and ClinViz. The company was founded on July 10, 2008 by Stephen Ayala and Tim S. Immel and is headquartered in Durham, NC.

Vital Venture Capital LLC (Vital Venture) is a venture capital subsidiary of Vital Financial LLC founded in 2007 by Craig Asher, Nathaniel Brinn and Cyrus Brinn. The firm is headquartered in Bethesda, Maryland.

Boehringer Ingelheim Venture Fund is an evergreen venture capital fund which seeks investment opportunities in biotech across the globe. It targets investments unrelated to Boehringer Ingelheim’s key therapeutic areas. Specifically, it focuses on start-up companies engaging in patient care enhancements through pioneering science including new therapeutic platforms, new generation vaccines, and new generation protein & antibody technologies, among others. The fund makes initial equity investments of EUR 500 thousand to EUR 3 million in seed or series A rounds. It also makes follow-on investments over a five to seven year time period, bringing the total investment size per company to an amount of EUR 10 million to EUR 15 million. The fund seeks to acquire minority stakes (usually greater than or equal to 10%) in target companies, as well as a seat on the board.

Shoefitr, Inc. helps online shoppers to find the correct size and best fitting shoes. Its technology is used on retailer's websites to assist online shoppers and will be the basis for a comparative shopping site that allows customers to search and compare shoes by fit. The company was founded in 2010 by Matt Wilkinson, Nick End and Breck Fresen and is headquartered in Pittsburgh, PA.

TARA Biosystems, Inc. develops organ-on-a-chip platform. It focuses on cardiac toxicology, heart failure drug discovery and personalized cardiology. The company was founded by Misti Ushio, Milica Radisic, Yimu Zhao, Gordana Vunjak-Novakovic, Kacey Ronaldson, Boyang Zhang and Blake Stevens on October 22, 2014 and is headquartered in New York, NY.

Tilos Therapeutics, Inc. designs and develops biotechnology products such as developing new treatments for cancer, fibrosis and autoimmune disease. It develops antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company was founded by Howard L. Weiner in 2016 and is headquartered in Lexington, MA.

Cantos Ventures LLC (Cantos Ventures) is a venture capital firm founded in 2016 by Ian Rountree. The firm is headquartered in San Francisco, California.

Cardioready, Inc. supplies cardiac equipment to organizations to reduce the impact of sudden cardiac arrest. The private company is based in Wallingford, PA.

ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier.

Trancos Ventures LLC (Trancos Ventures) is a venture capital firm founded in 2016 by Charles R. Lamphere, Norman L. Norris and Donald Asher. The firm is headquartered in Washington, District of Columbia.

Nephrosant, Inc. is a company dedicated to improving kidney health through noninvasive diagnostic tests. The company is based in Brisbane, CA. The company's flagship diagnostic test is QSant, a noninvasive urine-based test that supports early detection of kidney rejection risk. Nephrosant plans to develop centralized lab tests and point of care tests for kidney diseases and allograft monitoring for other organs. Founded in 2017 by Dr. Minnie Sarwal and UCSF physicians, the company has a team of world-class scientists, engineers, and clinicians who have licensed the founding team's clinical research to develop diagnostic tests for chronic kidney disease. Dr. Sarwal has been the CEO since 2017.

OMX Ventures LLC (OMX Ventures) is a venture capital firm founded in 2020. The firm is headquartered in Lincolnshire, Illinois.

Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau.

Matterworks, Inc. is a biotechnology company that specializes in metabolomics screening. The company is based in Somerville, MA. The company was founded by Jack Geremia and Mimoun Cadosch Delmar, with Jack Geremia serving as the CEO since incorporation.